is semaglutide new Medicare's $50 weight-loss drug program: Who qualifies and what are the concerns? Powerful new obesity drug poised

Their resistance could be due to defects in the system that transports it to the CNS or in the post-receptor transduction pathways of leptin ( Figure 3 ) [30,31]

Speranza A, Crinelli R, Scoccianti V, Geitmann A

This is where I go deeper

[93] [94] these cognition-enhancing effects of amphetamine are known to be partially mediated through the indirect activation of both dopamine D 1 receptor and 2 -adrenergic receptor in the prefrontal cortex

Cardiovascular Concerns: As we meander through the pathway of chronic use, the domain of cardiovascular safety, although often bathed in a positive light, also demands a thorough scrutiny